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AbstractDefects in genes involved in DNA damage repair (DDR) pathway are emerging as
novel biomarkers and targets for new prostate cancer drug therapies. A previous report
revealed an association between an exceptional response to cisplatin treatment and a
somatic loss of heterozygosity (LOH) of FANCA in a patient with metastatic prostate
cancer who also harbored a germline FANCA variant (S1088F). Although germline
FANCA mutations are the most frequent alterations in patients with Fanconi anemia,
germline alterations are less common in prostate cancer. We hypothesized that the
germline S1088F FANCA variant in combination with FANCA LOH was deleterious for
FANCA function and contributed to the patient’s exceptional response to cisplatin. We
show that although it properly localizes to the nucleus, the S1088F FANCA mutant
protein disrupts the FANC protein complex resulting in increased sensitivity to DNA
damaging agents. Because molecular stratification is emerging as a strategy for treating
men with metastatic, castrate-resistant prostate cancer harboring specific DDR gene
defects, our findings suggest that more biomarker studies are needed to better define
clinically relevant germline and somatic alterations.
[Supplemental material is available for this article.]
INTRODUCTION
DNA damage repair (DDR) genes are frequently altered in metastatic prostate cancer
and have been associated with sensitivity to poly (adenosine diphosphate [ADP]–ribose)
polymerase (PARP) inhibitor therapy. Data from a Phase 2 study of olaparib for patients
with metastatic castration-resistant prostate cancer (mCRPC) revealed that of the 16 out of
49 (33%) patients that had a response to olaparib, a significant number (14 of the 16
[88%]) of patients harbored one or more germline or somatic deleterious alterations in 12
DNA repair genes including a homozygous deletion of FANCA (Mateo et al. 2015). The
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full scope of biomarkers for molecular stratification for DDR targeted therapy or platinum
needs characterization.
PARP1 is a key protein in the DNA single-strand break (SSB) repair pathway of base
excision repair but also plays role in double-strand break (DSB) repair pathways (Schultz
et al. 2003; Schreiber et al. 2006; Krishnakumar and Kraus 2010), which is why PARP1
inhibition, which leads to persistent SSBs that are converted to DSBs, and BRCA1/2 loss of
function results in synthetic lethality in breast, ovarian, and prostate cancer (Fong et al.
2009). Therefore, deficiencies in proteins that are essential for homologous recombination
(HR) and which afford a “BRCAness” phenotype (e.g., FANC proteins; Taniguchi et al. 2003;
McCabe et al. 2006) sensitize cells to PARP1 inhibition. Several possible mechanisms for this
have been suggested (De Lorenzo et al. 2013), but recent studies suggest that PARP1 interacts
with the Fanconi anemia (FA) pathway to inhibit excessive nonhomologous end joining (NHEJ)
during DNA damage and inhibition of PARP in FANC-deficient cells have hyperactivation of
NHEJ and increased DNA damage producing a synthetic lethality phenotype (Du et al. 2016).
Fanconi anemia is a rare, genetically heterogeneous syndrome with increased predispo-
sition to a broad range of cancers and bone marrow failure (Brosh et al. 2016). Mutations in
20 genes encoding the Fanconi complementary group of proteins (FANCA-FANCU) have
been observed in FApatients (Dong et al. 2015; Park et al. 2016). FANCproteins are involved
in chromosomal stability and cellular resistance to DNA interstrand cross-linkers (ICLs) such
as mitomycin C (MMC) (Gurtan and D’Andrea 2006) or cisplatin. In cells without FANC gene
alterations, the FANC proteins FANCA, B, C, E, F and G, and L form a complex (Garcia-
Higuera et al. 2001; Meetei et al. 2003, 2004). During the S phase of the cell cycle,
FANCL monoubiquitinates and activates FANCD2, triggering FANCD2’s association with
chromatin and its accumulation in nuclear foci. These foci mark the sites in which DSB repair
occurs. Activated FANCD2 colocalizes with factors such as BRCA1, BRCA2/FANCD1, and
RAD51, which are involved in HR-mediatedDSB repair (Taniguchi et al. 2002). We previously
reported a prostate cancer patient (PM12) with small-cell neuroendocrine prostate cancer,
a relatively uncommon, aggressive prostate cancer phenotype with limited available treat-
ment options and poor overall survival (Wang et al. 2014), and who showed a complete
and durable remission after systemic cisplatin-based chemotherapy. Subsequent analysis
identified a germline variant in the FANCA gene (S1088F) (Table 1) with the tumor bearing
a loss of the wild-type allele (Beltran et al. 2015).
Somatic mutations in FANC genes occur with varying frequencies in prostate cancer with
∼6% of tumors harboring a homozygous FANCA deletion in localized TCGA (The Cancer
Genome Atlas Research 2015) and CRPC (SU2C; Robinson et al. 2015), which is notable
as other DNA repair defects are enriched in CRPC. Because FANCA is located at the
telomere of Chromosome 16, deletion calls were scored manually in these data sets.
Germline FANCA mutations in prostate cancer patients in the same cohorts are observed
with minor allele frequency of 0.065. Using preclinical prostate cancer models including
isogenic cell lines and patient-derived xenografts (PDXs) generated from the exceptional re-
sponder patient, we found that prostate cancer cells with FANCA deletion resulted in a high-
er sensitivity to cisplatin compared with cells with wild-type FANCA (Beltran et al. 2015). The
Table 1. FANCA variant summary
Gene Chromosome
HGVS DNA
reference
HGVS protein
reference
Variant
type
Predicted
effect dbSNP Genotype ClinVar ID
FANCA 16 NM_000135.2:
c.3263C>T
NP_000126.2:p.
Ser1088Phe
Substitution Ser>Phe 17,233,497 Heterozygous SCV000494044
HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations.
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impact of the germline FANCA (S1088F) variant on FANC complex function and cisplatin
sensitivity remains uncharacterized and is the focus of this current study.
RESULTS
FANCA S1088F Variant Enhances Sensitivity to DNA Damaging Agents
To investigate the consequence of the FANCA S1088F variant to drug sensitivity and DDR,
we included a comparison to three mutations from the Fanconi Anemia Mutation Database
(http://www.rockefeller.edu/fanconi/mutate/) that have been shown to result in strong
(R1055W; seven reports), mild (T1131A; 19 reports), and weak (D1359Y; two reports) impact
on MMC drug sensitivity and FANCD2 monoubiquitination (Adachi et al. 2002). We gener-
ated isogenic cell lines that express each of these FANCA mutant proteins, R1055W,
T1131A, D1359Y, or S1088F, as well as the wild-type FANCA in the FANCA null cell line
RA3087 (Zhou et al. 2012). Although moderate differences in protein levels were observed
between specific mutant proteins (e.g., between R1055W and S1088F [P = 0.0374]; S1088F
andD1359Y [P = 0.0439], and S1088F and control [P = 0.0126]), no significant differencewas
observed between cells expressing S1088F and wild-type FANCA (Fig. 1A). However, the
Figure 1. (A) Western blot of FANCA expression levels in isogenic cell lines. The graph indicates fold differ-
ence in the level of FANCA protein normalized to the FANCA endogenous control (∗ specifies P< 0.0439). (B)
Drug sensitivity to cisplatin representing IC50 of null, wild-type, and S1088F cell lines (∗ specifies significant
difference P< 0.004). (C ) Drug sensitivity to mitomycin C (MMC) illustrating the IC50 (∗ indicates significant dif-
ference P< 0.006).
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S1088F FANCA cell line showed an enhanced sensitivity to cisplatin (IC50 = 0.078 µM)
compared with cells expressing wild-type FANCA (IC50 = 0.45 µM, P = 0.004) but not as
sensitive as FANCA null cells (IC50 = 0.031 µM, P < 0.0001, Fig. 1B). Similarly, the S1088F
FANCA cells also showed an enhanced sensitivity to MMC (IC50 = 1.57 µM) compared
with wild-type FANCA (IC50 = 5.64 µM, P = 0.0006, Fig. 1C) but are less sensitive than
FANCA null cells (IC50 = 0.158 µM, P < 0.0001).
FANCA S1088F Variant Alters FANC Complex Function and Results in Loss of
Monoubiquination of FANCI
Intact FANC complex formation is essential for the monoubiquitination of FANCD2 (Garcia-
Higuera et al. 2001). We therefore queried if FANCA S1088F variant impacted FANCD2/
FANCI monoubiquitination. Cells were then treated with either dimethyl sulfoxide (DMSO)
(vehicle) or 1 µM MMC for 24 h. Cells expressing the FANCA mutations show changes in
the ratio of nonubiquitinated and monoubiquitinated FANCD2 following incubation in
1 µMMMC (Fig. 2A). As expected, cells expressing wild-type FANCA show both nonubiqui-
tinated and monoubiquitinated FANCD2 isoforms with the monoubiquitination levels in-
creasing from 20% to 70% following MMC treatment. No monoubiquitinated FANCD2
was observed either in vehicle or MMC-treated cell lines with no FANCA protein or
expressing the deleterious R1055W and D1359Y FANCA mutants (Fig. 2B). Compared
with wild-type FANCA, we observed S1088F and T1131A FANCA variants having lower
Figure 2. (A) Western blot expression of FANCD2 with 1 µMmitomycin C (MMC) treatment or vehicle. Arrow
indicates monoubiquitinated isoform and lower band is the nonubiquitinated FANCD2 protein. Longer/
shorter (L/S) ratios are also included. (B) Bar graph specifies the percentage of monoubiquitinated FANCD2
with and without MMC treatment (∗ specifies significant difference P< 0.328). (C ) Western blot expression
of FANCD2 and FANCI with 1 µM MMC treatment.
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levels of monoubiquitinated FANCD2 when untreated (11% and 13.5%, respectively) with
a significant difference seen between wild-type FANCA and S1088F FANCA cell lines
(P = 0.0328). Following MMC treatment we observe an increase in monoubiquitination of
FANCD2 in S1088F and T1131A FANCA expressing cells to 46% and 30%, respectively.
Both of these levels are significantly lower (P = 0.0235 and P = 0.0003, respectively) than
monoubiquitinated FANCD2 levels in wild-type FANCA cells. None of the cell lines express-
ing the different FANCA mutants yielded detectable FANCI monoubiquitination levels,
including cells expressing the S1088F FANCA mutant (Fig. 2C; Supplemental Fig. 1) follow-
ing MMC treatment.
FANCD2/FANCI protein complex foci formation is observed during DNA repair
(Smogorzewska et al. 2007) and is absent when there is a deleterious mutation in any of
the FANC core complex genes. We scored each cell as FANCD2-foci positive (five or more
fluorescent foci/nuclei) or negative (fewer than five fluorescent foci/nuclei) for the different
cell lines expressing each of the FANCA mutations at baseline or after MMC treatment
(results are summarized in Fig. 3A,B). At baseline, we observed little or no increase in the
number of FANCD2 foci-positive nuclei in cells expressing FANCA-null (4.2%), T1131A
(9.8%), and D1359Y (10.5%), all of which were significantly less than cells expressing wild-
Figure 3. (A) The graph shows the percentage of cells whose nuclei are identified as having five or greater
FANCD2 foci with either vehicle or 1 µM mitomycin C (MMC) treatment. Fisher exact tests between wild-
type FANCA and S1088F were performed and a significant difference was marked (∗, P< 0.0211). (B)
Typical FANCD2 foci formation in 1 µM MMC-treated cell lines: (left to right) B1 FANCA null, B2 FANCA
wild type, and B3 FANCA S1088F cell lines. Blue, DAPI; green, FANCD2. Scale bar, ∼10 µm.
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type FANCA (41.8%). As expected, MMC treatment increased the level of FANCD2 foci-
positive cells that expressedwild-type FANCA (53.8%) but had no effect on FANCA-null cells
(3.1%) or cells expressing deleterious FANCAmutations, R1055W (1.5%), T1131A (9.8%), or
D1359Y (8.8%). Cells expressing the S1088F FANCA variant also displayed a fewer number
of FANCD2 foci-positive nuclei (14.9%) compared with cells expressing wild-type FANCA
expressing cells at baseline, but, unlike the deleterious mutations, MMC treatment resulted
in a twofold increase (31%) in the number of FANCD2 foci-positive nuclei, suggesting that
the S1088F variant results in a partial loss of function on FANCA function.
Nuclear localization of FANCA has been shown to be coordinated through a nuclear
localization signal (NLS) in the FANCA protein, disruption of which leads to MMC sensitivity
(Garcia-Higuera et al. 1999; Lightfoot et al. 1999).We assessed the localization of the S1088F
FANCA variant and as a control, wild-type FANCA at baseline and after MMC treatment.
Both the wild-type FANCA and the S1088F variant showed predominantly nuclear localiza-
tion in the absence of MMC treatment suggesting that S1088F FANCA variant does not alter
nuclear localization of the protein (Fig. 4).
FANCA S1088F Variant Sensitizes Cells to PARP Inhibitors In Vitro and In Vivo
We queried if the S1088F variant sensitizes cells to olaparib. We found that the isogenic
cell line expressing the S1088F variant showed an increase in sensitivity to olaparib; how-
ever, this change was not significant (S1088F FANCA IC50 = 9.7 µM vs. wild-type FANCA
IC50 = 12.4 µM, P = 0.269) (Fig. 5A). As the in vitro models do not fully recapitulate the
FANCA status observed in the patient PM12 tumor (germline variant S1088F; Beltran
et al. 2015), we treated mice carrying a patient-derived xenograft (PDX) derived from
PM12 tumor (LTL545) with olaparib for 18 d. The LTL545 tumors showed significantly en-
hanced sensitivity (P < 0.0001) to olaparib comparedwith the vehicle-treated group (Fig. 5B).
DISCUSSION
In the Phase 2 clinical trial of olaparib reported by Mateo et al. 15 out of the 16 mCRPC pa-
tients that showed favorable response to the PARP1 inhibitor olaparib harbored alterations in
at least one of 12 DDR pathway genes assayed, 13 of which had BRCA1/2 or ataxia telangi-
ectasia mutated (ATM) alterations (Mateo et al. 2015). This suggests that there are potentially
other DDR gene alterations that may associate with olaparib response. DDR alterations have
also been associated with platinum sensitivity (Cheng et al. 2016). In a recent SU2C-PCF
study evaluating metastatic biopsies from patients with mCRPC, 19% of the 150 patients
harbored BRCA1, BRCA2, and ATM aberrations, whereas 3.7% of patients harbored other
DDR gene aberrations (Robinson et al. 2015). In an extended study to evaluate germline
alterations in DDR genes across 692 patients (Prichard et al. 2016), 11.8% of metastatic pros-
tate cancer patients were found to harbor deleterious germline DDR alterations, 64.5% of
which were BRCA1/2 orATM. We have previously published data showing an association be-
tween favorable response to cisplatin and FANCA loss (Beltran et al. 2015). Here, we show
that although FANCA S1088F protein properly localizes to the nucleus, it alters FANC com-
plex function, enhances sensitivity to DNA damaging agents, and sensitizes cells to PARP
inhibitors in vitro and in vivo. This is consistent with previous reports that showed mutations
in FANCAwere associatedwith differing sensitivity to DNA cross-linking agents (Adachi et al.
2002; Taniguchi et al. 2003; Kachnic et al. 2010) or nuclear localization (Ferrer et al. 2005). All
mutant FANCA expressing cell lines we analyzed including S1088F show no monoubiquiti-
nation of FANCI even after MMC treatment. The pathway by which FANCI and FANCD2 are
monoubiquitinated is becoming better understood (Smogorzewska et al. 2007; Castella
et al. 2015; Liang et al. 2016; Swuec et al. 2016; van Twest et al. 2016). A previous study
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has shown that a mutation in FANCI results in a protein that is unable to be monoubiquiti-
nated and reduced FANCD2 monoubiquitination (Smogorzewska et al. 2007). Somatic mu-
tations in FANC genes occur with varying frequencies in prostate cancer with ∼6% of tumors
harboring a homozygous FANCA deletion, TCGA (The Cancer Genome Atlas Research
Figure 4. Cellular localization of FANCAprotein. Red, FANCA; blue, DAPI. Nuclear localization of null FANCA
control showing no FANCA signal with (A) no mitomycin C (MMC) and (B) 1 mMMMC. Nuclear localization of
wild-type FANCAwith (C) no MMC and (D) 1 mMMMC. Nuclear locatization of FANCA in the S1088F FANCA
cell line with (E) no MMC and (F) 1 mM MMC. Scale bar, ∼10 µm.
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2015) or SU2C (Robinson et al. 2015). Although less common than BRCA and ATM alter-
ations (19% combined mutation rate in mCRPC patients; Robinson et al. 2015), alterations
in FANCAmay also be informative in terms of inclusion criteria for PARP inhibitor or platinum
trials.
METHODS
Cell Culture
The fibroblast cell line RA3087, which lacks the FANCA protein, was used as the parental
cell line for the overexpression of the FANCA constructs. RA3087 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 15% fetal bovine serum (FBS) with pen-
icillin and streptomycin. 293T cells were cultured in DMEM with 10% FBS with penicillin and
streptomycin.
Generation of Mutant FANCA Constructs and Lentiviral Transduction into RA3087 Cells
Mutant FANCA expression plasmids were obtained by site-directed mutagenesis
(QuikChange II XL Site-Directed Mutagenesis Kit, Agilent) from a wild-type open reading
frame (ORF) construct (the primers used for generating FANCA mutations are listed
in Table 2). Mutant and wild-type FANCA ORFs were then polymerase chain reaction
(PCR)-amplified using high-fidelity Taq polymerase (Herculase II fusion DNA polymerases,
Agilent) and primers that generated a FANCA ORF with a carboxy-terminal Flag tag. PCR
fragments were cloned into pcr8/gw/topo entry vector (Invitrogen) and Gateway-cloned
into a lentiviral expression vector (pHAGE_CMV_IP_HAFLAG; kindly provided by A.
Smogorzewska) and Sanger sequence–verified. Each expression plasmid was transfected to-
gether with the packaging plasmids (SV40 Gag/Pol, SV40 VSVG, SV40 Rev, and SV40 Tat)
described previously (Mostoslavsky et al. 2005). Supernatant containing lentiviral particles
were collected, filtered, and placed on RA3087 cells with polybrene at a final concentration
of 8 µg/ml. Following 24 h incubation, the media containing the virus is removed, and fresh
completemedia is added. Seventy-two hours after infection, themedia is replaced with fresh
Figure 5. (A) Dose–response to olaparib indicating the IC50 of null, wild-type, and S1088F (∗ specifies signifi-
cant difference P < 0.0373). (B) Growth of the patient-derived xenograft (PDX) frompatient PM12 (LTL545) with
and without olaparib treatment over 18 d (∗, P < 0.0001).
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media containing puromycin at 1 µg/ml. Following 7 d of puromycin selection, cells were
collected to check for FANCA protein expression.
Drug Treatment
Cisplatin drug assays were performed as before (Beltran et al. 2015). Briefly, cells were seed-
ed on six-well tissue culture plates. Cell lines were treatedwith either vehicle (0.1%DMSO) or
increasing doses of cisplatin. Following 4 d incubation, cells were trypsinized, reseeded in
96-well plates at 1000 cells per well, and cultured for a further 4 d. MMC and olaparib
drug sensitivity assays were performed in a 96-well plate format where cells were seeded
at 1000 cells per well 24 h before drug treatment. Media was removed and replaced with
media containing the appropriate drug concentration. The cells were cultured for 4 d; the
media was replaced with fresh media containing the appropriate drug dose and cultured
for an additional 4 d. Cell viability was measured using Cell Titer-Glo luminescent assay
(Promega Corporation), as we have previously described (Beltran et al. 2013) and according
to the manufacturer’s instructions. Cell viability dose response data were first normalized to
data using the vehicle treated control and then analyzed using nonlinear regression in which
the log (inhibitor) concentration versus normalized response curves were generated and the
IC50 doses were calculated (GraphPad Software; www.graphpad.com).
Immunoblot Analysis
Protein lysates were prepared in RIPA buffer (radioimmunoprecipitation assay lysis buffer)
supplemented with protease inhibitor cocktail and phosphatase inhibitors (Thermo
Scientific). The total protein concentration of the soluble extract was determined using the
BCA protein assay kit (Thermo Scientific). For FANCA each protein sample (20 µg) was
resolved on a 4%–15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–
PAGE), transferred onto a PDF (polyvinylidene difluoride) membrane (Bio-Rad), and incubat-
ed overnight at 4°C with primary antibodies. The antibodies used were anti-FANCA 1/5000
(A301-980A, Bethyl Laboratories). Following three washes with Tris-buffered saline with
Tween 20 (TBST), the blot was incubatedwith horseradish peroxidase-conjugated secondary
antibody and immune complexes were visualized by enhanced chemiluminescence detec-
tion (Luminata Forte WBLUF0500, Millipore). The blot was also probed with monoclonal
antibody against anti-GAPDH 1/10000 (AB2302 Millipore). We performed three technical
replicates and plotted the mean and SEM. To resolve monoubiquitinated FANCD2 from
unubiquitinated FANCD2, protein samples were run on a 3%–8% Tris-acetate gel at 100 V
for 90 min. Transfer to PDF membrane overnight 25 v at 4°C followed by incubation with
anti-FANCD2 antibody 1/2000 (NB100-182, Novus Biologicals), horseradish peroxidase–
conjugated secondary antibody, and chemiluminescence detection. Each of the isogenic
cell lines has three biological replicates except T1131A which have two replicates. To
Table 2. List of primers used for site-directed mutagenesis of FANCA
FANCA-S1088F-F 5′-CCGCCTGCCTTCGTTTGTCCTCTGCGGCA-3′
FANCA-S1088F-R 5′-CTGCCGCAGAGGACAAACGAAGGCACC-3′
FANCA-R1055W-F 5′-GATTTTCCGCAGATGGCTCCAGGCTC-3′
FANCA-R1055W-R 5′-GAGCCTGGCGCCATCTGCGGCAAATC-3′
FANCA-T1131A-F 5′-CTGACACAGGACATCGCCGCCCACTTCTTCAG-3′
FANCA-T1131A-R 5′-CTGAAGAAGTGGGCGGCGATGTCCTGTGTCAG-3′
FANCA-D1359Y-F 5′-CTGCATGTTGCTGTGTACATGTACTTGAAGC-3′
FANCA-D1359Y-R 5′-GCTTCAAGTACATGTACACAGCAACATGCAG-3′
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demonstrate monoubiquitinated FANCI, previously FANCD2 blotted western blot mem-
branes were stripped which with Restore PLUS western blot stripping buffer (Thermo
Scientific) for 5 min then blocked for 30 min and incubated overnight at 4°C with anti-
FANCI antibody A7 (Santa Cruz) diluted 1/500, followed by horseradish peroxidase–conju-
gated secondary antibody and chemiluminescence detection.
Immunofluorescent Labeling of Cells
Five sterile 12-mm circular coverslips were placed in each of the wells of a six-well dish.
FANCA positive or negative cells were plated at a density of 1 × 105 to 2.5 × 105 cells per
well. The next day, cells were treated with vehicle or 1 µM MMC (Sigma-Aldrich) for 24 h.
Cells were washed twice in PBS. Following incubation in 0.5% Triton X-100 (Sigma-
Aldrich) for 5 min, followed by fixation in 3.7% formaldehyde, permeabilized in 0.5% NP-
40 in phosphate-buffered saline (PBS) for 10 min and washed once in PBS. Coverslips with
cells were incubated in PBG blocking solution (0.2% w/v cold water fish gelatin [Sigma-
Aldrich], 0.5% w/v BSA [Sigma-Aldrich] in PBS) for 20 min, and then were incubated with
FANCD2 (Novus Biologicals) primary antibody (1/1000) in PBG at room temperature for 2
h. Cells were washed three times for 5 min each in PBG and incubated in secondary antibody
(Alexa Fluor 488 Goat anti Rabbit; Life Technologies) (1/1000) dilution in PBG for 1 h at room
temperature. Cells were then washed three times for 5 min and coverslips were mounted on
slides in ProLong Gold AntifadeMountant with DAPI (Life Technologies). Foci formation was
analyzed on an Olympus BX51 under 100× oil objective. Fisher exact tests were performed
between groups. FANCA localization was performed as above with the Flag M2 antibody
(Sigma-Aldrich) (1/500) incubated for 1 h and secondary antibody (Alexa Fluor 548 Goat
anti Mouse; Life Technologies) (1/500) and incubated for 1 h.
Xenografts
Patient-derived xenografts were developed in collaboration with the Living Tumor
Laboratory (www.livingtumorlab.com), University of British Columbia, as previously de-
scribed (Lin et al. 2014; Beltran et al. 2015). For drug treatment studies, tumors were allowed
to grow for 18 d (n = 16 total tumors per model) and were treated with vehicle or olaparib
(intraperitoneal dosing of vehicle or olaparib, 50 mg/kg per day). Tumor volume based on
caliper measurements and final tumor weight were assessed. The tumor weights at the final
day were compared using a nonparametric method—the Wilcoxon rank-sum test. All tests
are two-sided with a 0.05 level of significance.
ADDITIONAL INFORMATION
Data Deposition and Access
Genetic variant data were submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) under
accession number SCV000494044.
Ethics Statement
Patient PM12 was enrolled prospectively on an Institutional Review Board (IRB)-approved
protocol at Weill Cornell Medicine (IRB #1305013903) and provided written informed
consent that allowed for fresh tissue and blood collection, tumor and germline sequencing
(results described in Beltran et al. 2015), and the development of a PDX model as part of
the current study. The patient consent states that de-identified information may be used
for research and participation may benefit society through an increased understanding of
how to treat advanced cancer. The patient consented to publication of this article.
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